Pneumococcal (23-valent) vaccine is under clinical development by Beijing Green Bamboo Biotechnology and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pneumococcal (23-valent) vaccine’s likelihood of approval (LoA) and phase transition for Streptococcal Pneumonia took place on 22 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pneumococcal (23-valent) vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pneumococcal (23-valent) vaccine overview

Pneumococcal polysaccharide (23-valent) vaccine is under development for the prevention of Streptococcus pneumoniae infections and unspecified indication. It is administered through the intramuscular route. The vaccine candidate constitutes of polysaccharide serotype-antigens conjugated with various protein carriers.

Beijing Green Bamboo Biotechnology overview

Beijing Green Bamboo Biotechnology (Green Bamboo Biotechnology) operates in healthcare sector. Green Bamboo Biotechnology is headquartered in Beijing, China.

Quick View Pneumococcal (23-valent) vaccine LOA Data

Report Segments
  • Innovator
Drug Name
  • Pneumococcal (23-valent) vaccine
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
  • Respiratory
Key Developers
  • Sponsor Company: Beijing Green Bamboo Biotechnology
  • Originator: Beijing Green Bamboo Biotechnology
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.